We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cellular Biomedicine Group has initiated its Phase I Clinical Trial of anti-CD20 Chimeric Antigen Receptor T-cell (CAR-T) targeting anti-CD19 treated, relapsed diffuse large B-cell lymphoma (DLBCL) and small B-cell lymphoma patients in China, and dosed th